FOXO1 and B-cell non-Hodgkin lymphoma: Moreover, studies in BL and B cell non-Hodgkin’s lymphomas have demonstrated FOXO1 mutation as a pro-oncogenic event in germinal center B cell–derived lymphomas owing to its pro-proliferative and antiapoptotic activity (59, 60).